HealthTech Bio Actives (HTBA) is making its first acquisition as it looks to move beyond its established portfolio of citrus flavonoids and active vitamin B12 ingredients and build a broader platform for innovation.

The Barcelona-based ingredients manufacturer has agreed to acquire US biotechnology company Specnova, a specialist in ingredient delivery technologies designed to improve the bioavailability, performance and efficacy of plant compounds, vitamins, minerals, amino acids and peptides.

The deal is strategically significant because it is not simply an expansion of HTBA’s existing ingredient range. It gives the company access to technologies that can change how active ingredients are delivered, while providing Specnova with access to HTBA’s international commercial network.

For food, beverage and supplement manufacturers, the combination points to a growing focus on the performance of an ingredient within a finished product.

Building growth through technology

HTBA has spent almost five decades developing and commercialising science-backed ingredients, particularly citrus flavonoids and active forms of vitamin B12. Its first acquisition signals an intention to use that foundation to accelerate growth through complementary technologies.

Specnova, founded in 2017 and headquartered in the US, brings patented and clinically validated delivery systems to the business.

Its LipoVantage platform uses liposomes to encapsulate active ingredients, helping protect them through the digestive system and support absorption. NovaQSpheres uses multi-layered beadlets to provide controlled release, potentially giving formulators greater flexibility when combining different actives.

The significance for HTBA is that these technologies can potentially be applied alongside its own portfolio and to future ingredient development.

“For almost 50 years, HTBA has been on a journey to deliver science-backed solutions centred on consumer-driven innovation,” said Alexandre Valls-Coma, CEO of HTBA.

He described the acquisition as a milestone in the company’s commitment to sustainable, long-term growth, adding that Specnova’s technologies are complementary to HTBA’s existing offering and provide “a catalyst to accelerate future developments”.

From ingredients to delivery

For manufacturers, one of the important implications of the deal is the potential shift from what an ingredient does to how effectively it can be delivered.

Bioavailability and bioefficacy are increasingly important considerations when developing functional products, particularly where consumers expect measurable benefits from relatively small quantities of active ingredients.

Delivery technology can also help formulators address practical development challenges, including controlled release, protection of sensitive compounds and the incorporation of multiple actives into a finished product.

That gives HTBA another route to differentiate its ingredients as competition increases across the nutraceutical, functional food and beverage markets.

The company already has a portfolio spanning health applications, including its MecobalActive active vitamin B12 and DiosVein Forte micronised flavonoid fraction. It is also preparing to launch Leanara, a GLP-1 companion ingredient combining bioflavonoids with advanced vitamin B12 technology.

The Specnova acquisition could provide another technological layer through which HTBA can develop and commercialise future ingredient solutions.

Strengthening the US position

The transaction also has a clear geographical dimension.

Although HTBA has international operations and a North American operations centre in Ohio, acquiring a US biotechnology business gives it a stronger presence in one of the world’s most important markets for functional ingredients and supplements.

For Specnova, the benefit works in the opposite direction.

Founder and CEO Sebastian Balcombe said the company had reached a point where the right partner could help it take the business to the next level.

Its technology, clinical research, intellectual property and customer service proposition will remain central to the business, he said, while HTBA’s network will broaden the markets in which Specnova can offer its technologies.

This creates a two-way growth model: HTBA gains technology and US capabilities, while Specnova gains international commercial reach.

Keeping the businesses independent

HTBA and Specnova will continue to operate independently following the agreement, while working together to enhance and develop their science-backed ingredient portfolios.

That structure is significant because it suggests the acquisition is intended to preserve Specnova’s specialist technology and development capabilities rather than absorb them immediately into HTBA’s existing operation.

For HTBA, the priority appears to be combining complementary capabilities while allowing each business to retain its strengths.

Valls-Coma described Specnova as a “natural fit” for HTBA because its technologies complement the existing portfolio and can help unlock new opportunities for customers.

For manufacturers, the potential value will ultimately be measured by what comes out of that collaboration: new ingredient formats, improved delivery, stronger evidence and solutions that make it easier to formulate products around specific consumer health needs.

A first step in a broader strategy

The acquisition is therefore more significant than the addition of another ingredient supplier to HTBA’s portfolio.

It represents a move towards building technology-enabled growth around its existing ingredient expertise.

Rather than relying solely on expanding volumes of established ingredients, HTBA is investing in capabilities that could allow it to create differentiated solutions and develop new applications.

The acquisition also gives the company a stronger platform from which to pursue opportunities in the US while opening Specnova’s technologies to HTBA’s established international customer base.

The transaction is expected to close in the coming weeks, subject to customary conditions.

Both businesses will subsequently appear at SupplySide Global 2026 in Las Vegas, where HTBA will showcase its ingredient portfolio and official US launch of Leanara®, while Specnova will present its delivery technologies and branded ingredients.

The exhibition will provide an early indication of how the two portfolios can be positioned together. More importantly, the acquisition sets out a clear direction for HTBA’s next stage of growth: combining ingredient science with delivery technology to create more differentiated, evidence-led solutions for manufacturers.